Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q4 2025

Q4 2025 biggest moves
  • BMYBMY

    Bristol-Myers Squibb

    Sold out

    was 1.6% of portfolio

  • CELCCELC

    Celcuity

    2.3× the shares

    now 2.2% of portfolio

  • CNCCNC

    Centene

    Cut 29%

    now 3.4% of portfolio

  • INDVINDV

    INDIVIOR

    Cut 51%

    now 1.6% of portfolio

147 changes in all

Top Holdings150 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

17.2M$1.7B22.2%——
18 qtrssince 2021-Q3
Decreased
0
306.9M$427.5M5.5%——
1 qtr
New
96
COGT

Cogent Biosciences, Inc.

9M$321.2M4.1%$12.67+180.37%
21 qtrssince 2020-Q4
Decreased
0
PRAX

Praxis Precision Medicines, Inc.

903,351$266.3M3.4%$58.53+403.57%
4 qtrssince 2025-Q1
Increased
61
CNC

Centene Corporation

6.4M$265.3M3.4%$46.26-11.04%
25 qtrssince 2019-Q4
Decreased
0
VTRS

Viatris Inc.

20.2M$251.6M3.2%$11.15+9.08%
21 qtrssince 2020-Q4
Decreased
0
RVMD

Revolution Medicines, Inc.

2.9M$230.6M2.9%$29.54+169.67%
24 qtrssince 2020-Q1
Decreased
0
UTHR

United Therapeutics Corporation

425,993$207.6M2.7%$298.00+63.51%
4 qtrssince 2025-Q1
Unchanged
0
VERA

Vera Therapeutics, Inc.

4.1M$205.6M2.6%$26.87+88.48%
4 qtrssince 2025-Q1
Increased
58
70M$180.7M2.3%——
7 qtrssince 2024-Q2
Unchanged
0
CELC

Celcuity Inc.

1.7M$171M2.2%$78.20+27.55%
2 qtrssince 2025-Q3
Increased
84
NBIX

Neurocrine Biosciences, Inc.

1.2M$168M2.1%$107.87+31.48%
20 qtrssince 2021-Q1
Unchanged
0
IONS

Ionis Pharmaceuticals, Inc.

2M$156.6M2.0%$65.42+20.93%
2 qtrssince 2025-Q3
Unchanged
0
NAMS

NewAmsterdam Pharma Company N.V.

4.2M$146.1M1.9%$23.65+48.36%
8 qtrssince 2024-Q1
Decreased
0
INSP

Inspire Medical Systems, Inc.

1.5M$138.9M1.8%$84.85+8.69%
3 qtrssince 2025-Q2
Increased
64
LEGN
LEGN
ADR

Legend Biotech Corporation

5.9M$129M1.6%$27.78-21.75%
5 qtrssince 2024-Q4
Increased
77
BKD

Brookdale Senior Living Inc.

11.6M$125.6M1.6%$4.41+144.65%
25 qtrssince 2019-Q4
Decreased
0
INDV
INDVDelisted

INDIVIOR PLC

3.4M$121.7M1.6%$8.28—
6 qtrssince 2024-Q3
Decreased
0
ARWR

Arrowhead Pharmaceuticals, Inc.

1.8M$121.7M1.6%$49.11+35.19%
2 qtrssince 2025-Q3
Increased
74
LRMR

Larimar Therapeutics, Inc.

30.6M$116.6M1.5%$5.59-31.90%
23 qtrssince 2020-Q2
Unchanged
0
$7.8B
AUM
150
Positions
Q4 2025
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2024-Q3$6,692,805,83111.3517011135%
2024-Q4$5,280,006,191-21.1092279632%
2025-Q1$5,064,779,427-4.07625969013%
2025-Q2$5,509,809,2648.78675652937%
2025-Q3$6,550,740,15118.8923216236%
2025-Q4$7,830,165,97019.5310116034%
Activity profile
$ moved · Q4'25
New24%Increased27%Decreased24%Exited25%
Composition
Equity vs derivatives
Equity>99%Puts<1%Calls0%
Holding period
Avg 2.7 years
<1Q6%1-4Q7%1-2Y22%2Y+65%

Deerfield Management Company, L.P. manages $7.8B across 150 positions as of Q4 2025. Top holdings: NUVL (22.2%), BROOKDALE SR LIVING INC (5.5%), COGT (4.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$8B
NUVL22.16%
BROOKDALE SR5.46%
COGT4.10%
PRAX3.40%
CNC3.39%
VTRS3.21%
RVMD2.94%
UTHR2.65%
VERA2.63%
MIRUM PHARMA2.31%
Other2.18%

Portfolio allocation by GICS sector

Sectors6
Healthcare99.45%
Real Estate0.40%
Financial Services0.06%
Consumer Cyclical0.04%
Consumer Defensive0.02%
Industrials0.02%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used